Original Contribution | Published:

Pancreas and Biliary Tract

Use of Antidiabetic Agents and the Risk of Pancreatic Cancer: A Case–Control Analysis

The American Journal of Gastroenterology volume 107, pages 620626 (2012) | Download Citation

Abstract

OBJECTIVES:

The objective of this study was to explore the association between use of metformin or other antidiabetic drugs, diabetes, and the risk of pancreatic cancer.

METHODS:

We conducted a case–control study using the UK-based General Practice Research Database (GPRD). Cases had a first-time diagnosis of pancreatic cancer, and six controls per case were matched on age, sex, calendar time, general practice, and number of years of active history in the GPRD before the index date. Results were further adjusted in multivariate logistic regression analyses for potential confounders such as body mass index, smoking, alcohol consumption, and diabetes duration.

RESULTS:

In all, 2,763 case patients with a recorded diagnosis of pancreatic cancer were identified. Mean age±s.d. was 69.5±11.0 years. Long-term use (≥30 prescriptions) of metformin was not associated with a materially altered risk of pancreatic cancer (adjusted odds ratio (adj. OR): 0.87, 95% confidence interval (CI): 0.59–1.29), but there was a suggestion of effect modification by gender, as long-term use of metformin was linked to a decreased risk in women (adj. OR: 0.43, 95% CI: 0.23–0.80). Both use of sulfonylureas (≥30 prescriptions, adj. OR: 1.90, 95% CI: 1.32–2.74) and of insulin (≥40 prescriptions, adj. OR: 2.29, 95% CI: 1.34–3.92) were associated with an increased risk of pancreatic cancer.

CONCLUSIONS:

Use of metformin was associated with a decreased risk of pancreatic cancer in women only, whereas use of sulfonylureas and of insulin was associated with an increased risk of pancreatic cancer.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , . Epidemiology of pancreatic cancer: an update. Dig Dis 2010;28:645–656.

  2. 2.

    . Pancreatic cancer. N Engl J Med 2010;362:1605–1617.

  3. 3.

    , , et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893–2917.

  4. 4.

    , , et al. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg 2008;393:535–545.

  5. 5.

    , . Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam Cancer 2009;8:109–117.

  6. 6.

    , , et al. Alcohol drinking and pancreatic cancer risk: a meta-analysis of the dose-risk relation. Int J Cancer 2010;126:1474–1486.

  7. 7.

    , . Well-done meat intake, heterocyclic amine exposure, and cancer risk. Nutr Cancer 2009;61:437–446.

  8. 8.

    , , . A meta-analysis of obesity and the risk of pancreatic cancer. Br J Cancer 2003;89:519–523.

  9. 9.

    , , . Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer 2007;96:507–509.

  10. 10.

    , , et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005;92:2076–2083.

  11. 11.

    , . Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995;273:1605–1609.

  12. 12.

    , , et al. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control 2011;22:189–197.

  13. 13.

    , , et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008;134:981–987.

  14. 14.

    , , et al. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol 2009;10:88–95.

  15. 15.

    , , . The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766–1777.

  16. 16.

    , , et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304–1305.

  17. 17.

    , , et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620–1625.

  18. 18.

    , , et al. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010;33:1304–1308.

  19. 19.

    , , et al. Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol 2011;123:200–204.

  20. 20.

    , , et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482–488.

  21. 21.

    , . The general practice research database: role in pharmacovigilance. Drug Saf 2004;27:871–881.

  22. 22.

    , , et al. Validity of the general practice research database. Pharmacotherapy 2003;23:686–689.

  23. 23.

    , , . Clinical information for research; the use of general practice databases. J Public Health Med 1999;21:299–304.

  24. 24.

    , , et al. Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: a population based case-control study. J Am Acad Dermatol 2008;58:421–429.

  25. 25.

    , , et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008;168:820–825.

  26. 26.

    , , et al. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 2011;20:337–344.

  27. 27.

    , , . Diabetes and pancreatic cancer: chicken or egg? Pancreas 2011;40:339–351.

  28. 28.

    , , . Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 2004;127:1044–1050.

  29. 29.

    , , . Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991;302:766–768.

Download references

Author information

Affiliations

  1. Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland

    • Michael Bodmer
    • , Claudia Becker
    •  & Christoph R Meier
  2. Emergency Department, University Hospital Basel, Basel, Switzerland

    • Michael Bodmer
  3. Division of Endocrinology, Diabetes and Clinical Nutrition, University Hospital Basel, Basel, Switzerland

    • Christian Meier
  4. Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, Massachusetts, USA

    • Susan S Jick
    •  & Christoph R Meier
  5. Hospital Pharmacy, University Hospital Basel, Basel, Switzerland

    • Christoph R Meier

Authors

  1. Search for Michael Bodmer in:

  2. Search for Claudia Becker in:

  3. Search for Christian Meier in:

  4. Search for Susan S Jick in:

  5. Search for Christoph R Meier in:

Competing interests

Guarantor of the article: Christoph R. Meier.

Specific author contributions: Concept and design, acquisition of data, and drafting of the manuscript: Christoph R. Meier and Michael Bodmer; analysis and interpretation of data: Claudia Becker, Christoph R. Meier, Michael Bodmer, Susan S. Jick, and Christian Meier; critical revision of the manuscript for important intellectual content: Michael Bodmer, Christoph R. Meier, Christian Meier, Susan S. Jick, and Claudia Becker; statistical analysis/expertise: Claudia Becker and Christoph R. Meier; administrative, technical, or material support: NA.

Financial support: This work was partially funded by the Swiss Cancer League (Krebsliga Schweiz) and the Research Fund of the University of Basel, Switzerland but the work was independently done by the authors.

Potential competing interests: None.

Corresponding author

Correspondence to Christoph R Meier.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ajg.2011.483

Further reading